Go to ...

ModernGraham

Value Investing Research Since 2006

RSS Feed

Friday, June 22, 2018

Pharmaceuticals

Allergan PLC Valuation – May 2018 $AGN

Allergan plc Ordinary Shares does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history.

Incyte Corp Valuation – April 2018 $INCY

Incyte Corporation does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

Regeneron Pharmaceuticals Inc Valuation – April 2018 $REGN

Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

Alexion Pharmaceuticals Inc Valuation – April 2018 $ALXN

Alexion Pharmaceuticals, Inc. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios.

Vertex Pharmaceuticals Inc Valuation – April 2018 $VRTX

Vertex Pharmaceuticals Incorporated does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

AmerisourceBergen Corp Valuation – April 2018 $ABC

AmerisourceBergen Corp. does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the high PEmg and PB ratios.

Perrigo Company PLC Valuation – April 2018 $PRGO

Perrigo Company plc Ordinary Shares does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the high PEmg and PB ratios.

AbbVie Inc Valuation – April 2018 $ABBV

AbbVie Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

Eli Lilly and Co. Valuation – March 2018 $LLY

Eli Lilly And Co does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the high PEmg and PB ratios.

Zoetis Inc Valuation – March 2018 $ZTS

Zoetis Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.

Older Posts››